Hearing on "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight"
The Subcommittee on Health of the Committee on Energy and Commerce held a hybrid legislative hearing that included both in-person and remote attendance on Thursday, March 17, 2022, at 10:30 a.m. This hearing took place in the John D. Dingell Room, 2123 of the Rayburn House Office Building, as well as remotely using Cisco Webex online video conferencing. The hearing is entitled, "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight."
Memorandum from Chairman Pallone to the Subcommittee on Health
Opening Statement from Chairman Pallone as prepared for delivery
Opening Statement from Subcommittee Chairwoman Eshoo as prepared for delivery
H.R. 1730, the “Speeding Therapy Access Today Act of 2021”
H.R. 2565, the “FDA Modernization Act of 2021”
H.R. 3085, the “Equity in Neuroscience and Alzheimer’s Clinical Trials Act of 2021” or the “ENACT Act of 2021”
H.R. 3927, the “Manufacturing API, Drugs, and Excipients in America Act” or the “MADE in America Act”
H.R. 4472, the “Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021” or the “BENEFIT Act of 2021”
H.R. 4511, the “FDA Advancing Collection of Transformative Science Act” or the “FACTS Act”
H.R. 5030, the “Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act” or the “DIVERSE Trials Act”
H.R. 5566, the “Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021” or the “FORWARD Act of 2021”
H.R. 5585, the “Advanced Research Project Agency–Health Act” or the “ARPA-H Act”
H.R. 6000, the “Cures 2.0 Act”
H.R. 6584, the “Diverse and Equitable Participation in Clinical Trials Act” or the “DEPICT Act”
H.R. 6888, the “Helping Experts Accelerate Rare Treatments Act of 2022”
H.R. 6963, the “Accelerated Approval Integrity Act of 2022”
H.R. 6972, the “Give Kids a Chance Act”
H.R. 6973, the “Enhanced Access to Affordable Medicines Act”
H.R. 6988, the “Drug Manufacturing Innovation Act”
H.R. 6996, the “Accelerating Access for Patients Act”
H.R. 7006, the “Improving the Nation’s Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act” or the “INSPECTIONS Act”
H.R. 7008, the “Pre-Approval Information Exchange Act”
H.R. 7032, the “Increasing Transparency in Generic Drug Applications Act”
H.R. 7035, the “Biologics Market Transparency Act"
H.R. 7047, a bill to amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes
Jeff Allen, Ph.D.
President and CEO
Friends of Cancer Research
Cartier Esham, Ph.D.
Chief Scientific Officer
Executive Vice President, Emerging Companies
Biotechnology Innovation Organization
Senior Vice President, Sciences and Regulatory Affairs
Association for Accessible Medicines
Ruben Mesa, M.D.
Executive Director, Mays Cancer Center
UT Health San Antonio MD Anderson
Reshma Ramachandran, M.D.
Chair, Doctors for America FDA Task Force
Physician-Fellow, Yale National Clinician Scholars Program
Yale School of Medicine
Lucy Vereshchagina, Ph.D.
Vice President, Science and Regulatory Advocacy
Pharmaceutical Research and Manufacturers of America